Fibroblast growth factor 21 (FGF21) is a member of the endocrine FGF family that acts as a metabolic regulator of both glucose and lipid metabolism. Similar to fibroblast growth factor 23 (FGF23), serum FGF21 levels rise progressively with the loss of renal function, reaching 20 times normal values in end-stage renal disease. In patients with chronic kidney disease (CKD), higher serum FGF21 levels correlate with poorer metabolic profile, higher inflammatory markers, more comorbidities, and higher mortality. The high serum FGF21 levels are above and beyond what can be explained by the loss of FGF21 renal clearance, suggesting increased production and/or impaired non-renal clearance. In diabetic nephropathy, serum FGF21 levels correlate with the severity of albuminuria and faster loss of glomerular filtrate rate and can potentially be a biomarker of poor prognostic. The observational and associative human data contrast sharply with in vitro and in vivo preclinical experimental data, which is more in line with a protective role of FGF21 in chronic nephropathies. We here review the physiology of FGF21, and the literature regarding its behavior in CKD with particular focus on diabetic nephropathy. Finally, we speculate on the role of FGF21 in CKD.
Introduction
Fibroblast growth factor (FGF) 21 is one of three members of the endocrine FGF subfamily that plays an important role in glucose and lipid metabolism [1] . Like FGF23, serum FGF21 levels progressively rise in chronic kidney disease (CKD), reaching 20 times the normal range [2] . Currently, there are observational studies with CKD patients showing interesting correlations, but the mechanisms of, reasons for, and functional sequelae of FGF21 elevation in CKD remain elusive. There is a positive correlation of FGF21 level with mortality in dialysis patients [3] . In type 2 diabetic (T2D) patients, serum FGF21 levels correlate with nephropathy onset, albuminuria, and risk of progression to end-stage renal disease (ESRD) [4] [5] [6] . In contrast, in experimental in vitro and in vivo models, FGF21 has been proposed to exert protective effects against glucotoxicity and lipotoxicity, and to reduce inflammation, oxidative stress and fibrosis [7] [8] [9] . Is FGF21 a friend, a foe, or mere bystander? These are important questions that direly require answers. We will discuss the physiology of FGF21 and review the existing data about FGF21 in CKD and diabetic nephropathy.
The mammalian FGF superfamily
FGFs are a superfamily of structurally-related peptides of 150-300 amino acids with a conserved core of approximately 120 amino acids. There are 22 members divided into 1 3 7 subfamilies based on sequences and functional properties. FGF15 and 19 are the same gene in rodent and human, respectively, now renamed FGF15/19. Despite the structural homology, FGFs have very broad actions, from cell proliferation and differentiation in embryonic stages of morphogenesis and organogenesis, to cytoprotection, repair, and metabolic regulation in adults [10] .
Canonical FGFs are secreted autocrine/paracrine proteins which represent the majority of FGFs with 15 members in 5 subfamilies. FGFs have intracrine, paracrine, and endocrine actions. The action of FGFs occurs through the binding and activation of FGF receptors (FGFRs) which are ubiquitous tyrosine kinase receptors and require heparan sulfate as a cofactor. It is proposed that canonical FGFs get sequestered and act only locally and have no significant circulating levels. Usually, they affect morphogenesis, organogenesis, development, and repair [11] .
Endocrine FGFs also bind and activate membrane FGFRs, but they have low intrinsic heparin-binding affinity and require a specific protein cofactor (α or β-klotho) in target organs to work. They are released and act at distant sites as endocrine hormones [11] .
Intracellular FGFs are not secreted and believed to act in an intracrine manner, independent of FGFRs [11] . They bind to intracellular domains of sodium-dependent voltage channels, regulating the electrical excitability of neurons [12] . Since they do not interact with receptors, it is debatable whether they should be called FGFs.
Gene, biochemistry and signaling of FGF21
The FGF21 gene is on human chromosome 19, with 3 exons coding a 209 amino acids peptide (pre-FGF21). The FGF21 protein is highly conserved with 89% homology between mouse and rat and 75% between mouse and human [13] . After cleavage of an N-terminal 28 amino acids signal peptide, secreted FGF21 is 180-182 amino acids depending on the species (about 21-kD). FGF21 crosses the blood-brain barrier [14] and is expected to cross the glomerular capillary as well, resulting in glomerular filtration, tubular uptake and degradation, and urinary excretion [15] . There are actually no data on urinary FGF21 levels, but renal clearance is considered the main route of excretion by inference. If one extrapolates from FGF23, about 40% of the circulating FGF23 is extracted after passage through the kidney [16] . FGF23 is a larger peptide than FGF21 (32 kDa vs. 21 kDa), so FGF21 may have an even higher urinary excretion rate.
In addition to renal clearance, circulating FGF21 can be cleaved and inactivated by fibroblast activation protein (FAP) [17, 18] . FAP is an endopeptidase that cleaves human FGF21 at proline 171 /serine 172 near the C-terminus, which abrogates the ability of FGF21 to bind to its receptor [18] .
Truncated FGF21 exhibits a 400-fold reduction in the ability to activate FGF signaling in adipocytes [19] . The half-life of recombinant human FGF21 injected intravenously in mice and primates is 0.5 h and 2 h, respectively, but the biologic half-life is conceivably much longer than the pharmacologic one [20] .
Like other endocrine FGFs (FGF23 and FGF15/19), FGF21 depends on Klotho as a cofactor to signal (β-klotho for FGF21) [21] . Compared to canonical FGFs, FGF21 has low intrinsic binding affinity for both heparan sulphate and FGFR itself. This low affinity to heparan sulphate enables FGF21 to depart from the cell, while its low affinity for the FGFR safeguards against nonspecific off-target signaling [22] .
The tissue-specific expression of β-klotho determines the ability of that tissue to respond to FGF21 [22] . The association of β-klotho with its cognate FGFRs leads to high binding affinity to FGF21. β-Klotho preferentially binds to FGFRc splice isoform engaging the conserved hydrophobic groove in the D3 domain, which inhibits signaling by paracrine FGFs [23] . This property is believed to dedicate FGFRs in target cells exclusively to binding the endocrine FGFs and avoiding interference from paracrine FGFs. FGF21 can activate several FGFRc splice isoforms like FGFR1c, 2c, 3c, and FGFR4, but it has higher affinity for the FGFR1c isoform [23] .
Recent studies on the ternary complex between FGF21, FGFR1c and β-klotho, support the 1:2:1 model rather than the 2:2:2 model for α-klotho and FGF23. β-klotho confers high-affinity binding to FGFRs for FGF21, and FGFR1c functions as the subunit that mediates receptor dimerization and intracellular signaling [24] . In the plasma membrane of unstimulated cells, β-klotho and FGFR1c monomers are in equilibrium with β-klotho-FGFR1c heterodimers. The binding of FGF21 to β-klotho via the C-terminal tail, and the bivalent binding of the FGF21 core to two FGFR1c molecules, shifts the equilibrium towards the FGF21-FGFR1c-β-klotho complex, FGFR1c dimerization, juxtaposition of the intracellular tyrosine kinase domains, kinase activation by transphosphorylation, and eventually cell signaling [24] . The intracellular tyrosine kinase domains activate the fibroblast receptor substrate alpha (FRS2α) by phosphorylation, setting in motion the Ras/Raf/ MAPK or PI3K/AKT signaling pathways, resulting in a broad downstream gene transcription profile [22] .
Synthesis and functions
FGF21 is primarily produced in the liver providing serum levels under physiological conditions. Other sites include white adipose tissue (WAT), brown adipose tissue (BAT), pancreas, skeletal muscle, heart, and kidneys. These organs are usually targets of FGF21, but in special conditions they can produce FGF21 [25] .
The first FGF21 function described in 2005 was to increase cellular glucose uptake. FGF21 transgenic mice are resistant to diet-induced obesity, and administration of rFGF21 in murine obesity models (ob/ob and db/db mice) reduces plasma glucose and triglycerides [1] . FGF21 is a metabolic regulator of glucose metabolism by reducing serum glucose levels, increasing insulin sensitivity, and promoting gluconeogenesis; as well as it regulates lipid metabolism by reducing serum triglyceride (TG) levels and by promoting ketogenesis and fatty acid oxidation in response to fasting [26] . In addition, FGF21 induces thermogenesis in BAT in mice with cold stimulation and promotes the emergence of brown fat-like cells in WAT, the so-called "browning" process. FGF21 also induces weight loss in mice, primates and humans by increasing basal energy expenditure ( Fig. 1) [20, 26, 27] .
The hepatic expression of FGF21 is induced by peroxisome-proliferator-activated receptor-α (PPARα), which in turn is activated by free fatty acids released into circulation by fasting/starvation-induced lipolysis or by a ketogenic diet [25] . The FGF21 secretion induced by fasting/starvation is faster and more intense in mice than in humans, in whom a significant elevation of FGF21 levels occurs after 7 days of fasting [28] .
PPARα agonists, like fenofibrate, substantially increase the hepatic expression of FGF21 [29] . Many anti-diabetic drugs also increase serum levels of FGF21, which may mediate some of their beneficial effects [30] . Another stimulus for the hepatic expression of FGF21 is deprivation of amino acids, such as methionine, by a protein-poor diet [31] .
Extra-hepatic tissues can express significant amounts of FGF21 in pathophysiological conditions. BAT may change from being a target to become a source of FGF21, especially at times of thermogenic activation [32] . In WAT, expression of FGF21 is regulated by PPARγ in response to the abundance of circulating free fatty acids (Fig. 2) [25] .
There is considerable plasticity in sources of FGF21. Although not a significant source under physiological conditions, skeletal muscle expresses FGF21 after physical exercise [33] , or in pathological conditions like sepsis and mitochondrial myopathy [34] . Release of FGF21 by muscle cells in response to mitochondrial dysfunction may represent a mechanism by which muscle perceives the energy status and releases FGF21 to favor systemic metabolic adaptations [34] . The myogenic factor MyoD together with the activating transcription factor 4 (ATF4) is the main controller of FGF21 gene transcription in muscle in response to mitochondria-driven signals involving reactive oxygen species production [35] .
Myocardium can express FGF21 in certain physiological conditions such as during pregnancy [36] and physical exercise [37] , as well as in pathological conditions such as myocardial stress [38] . In these cases, FGF21 appears to have local action mainly and is considered a protective cardiomyokine [39] . On the other hand, the myocardium can be a target of systemic FGF21 released from the liver or adipose tissue, in models of ischemia or acute myocardial infarction [40, 41] . Free fatty acids stimulate FGF21 secretion by the liver. Circulating FGF21 acts mainly on white adipose tissue to stimulate glucose uptake, lipolysis, β-oxidation of fat and adiponectin secretion. Furthermore, FGF21 induces browning and thermogenesis. In the brain, FGF21 regulates the circadian cycle, increases release of corticotropin-releasing factor, sympathetic nerve activity, while decreasing the release of gonadotropin-releasing hormone. FGF21 can be inactivated by FAP cleavage and excreted into the urine Interestingly, in each tissue, the activation of FGF21 expression can be driven by different stressful stimuli, which activate different signaling pathways, and there appears to be no demonstrable negative feedback loop. FGF21 is viewed as a stress-responsive factor that participates in the integrated stress response which maintains tissue homeostasis in an autocrine/paracrine manner and provides an endocrine coordination of inter-organ adaptation to stress [42] .
Accordingly, either extrinsic stressors such as hypoxia, oxidative stress and glucose or amino acids deprivation, or intrinsic stressors such as mitochondrial or endoplasmic reticulum stress can drive the expression of FGF21 in several tissues [42, 43] . Once secreted, FGF21 participates in protective autocrine/paracrine loops that increase cellular stress resistance, through mechanisms such as autophagy enhancement, mitochondrial respiratory capacity intensification and activation of anti-oxidation and inflammation reduction mechanisms [42] . At the systemic level, FGF21 increases glucose tissue uptake, β-oxidation of free fatty acids and secretion of adiponectin and corticosterone, therefore enhancing organism adaptation to stress [42] .
Consequently, FGF21 can be viewed as an ideal stressresponsive factor since organelle stress stimulates its expression and secretion from many peripheral tissues into the circulation, thus attempting to restore whole-body homeostasis.
FGF21 levels and sources in CKD
As a small polypeptide, FGF21 is likely filtered and excreted in the urine, as an important route of FGF21 clearance. As the glomerular filtration rate (GFR) declines, serum FGF21 levels rise, reaching 10-to 23-fold normal levels in ESRD. Highest levels appear to be present in hemodialysis, diabetic and male patients [2, 15] . Patients on peritoneal dialysis (PD), despite the glucose supply from the dialysis solution, have lower circulating FGF21 levels than patients on hemodialysis, possibly due to the better residual renal function in these patients [44, 45] . But whether peritoneal dialysis is able to clear circulating FGF21 is still unknown. Serum FGF21 levels are higher post-hemodialysis indicating that hemodialysis does not effectively clear circulating FGF21 even with use of high flux membranes [15] . FGF21 concentrations were shown to be higher post dialysis-filter, but the concentration of FGF21 was not corrected for the degree of hemoconcentration [46] . There are no data about FGF21 removal by convection, but this method might be more effective, in the same way as shown for FGF23 [47] .
The decrease or absence of FGF21 renal clearance in anuric patients is insufficient to explain the increase in serum levels that reaches over 20 times the physiological levels. After dialysis initiation, creatinine and GFR no longer In fatty liver disease, FGF21 expression and secretion are increased and act in a paracrine loop reducing lipotoxicity and inflammation. In mitochondrial myopathies, skeletal muscles become a source of FGF21 acting in a paracrine loop that increases glucose uptake and β-oxidation. In cardiomyopathy or after acute myocardial infarction, FGF21 expression increases and protects cardiomyocytes through a paracrine loop increasing β-oxidation and autophagy, while it decreases lipotoxicity, inflammation and apoptosis. In diabetic nephropathy, FGF21 protects against lipotoxicity and inflammation, and reduces fibrosis. Fatty liver disease and mitochondrial myopathies increase serum FGF21 levels, but it is not known if cardiomyopathy, diabetes nephropathy and pancreatitis can do the same correlate independently with circulating levels of FGF21, and it is possible that other non-renal factors could play the major role [3, 15] .
Another knowledge gap about FGF21 in CKD is its source. Normally, the liver is the main source of circulating FGF21, but under pathological conditions adipose tissue, skeletal muscle and even the myocardium can become a source of FGF21 and contribute to elevation of circulating FGF21 levels (Fig. 3) [32, 34, 38] .
It is conceivable that factors such as insulin resistance, metabolic syndrome, chronic inflammation and increased oxidative stress (invariably present in ESRD patients) may contribute to the elevation of serum FGF21 levels in ESRD. Uremic toxins, metabolic acidosis, anemia and hyperphosphatemia may also contribute to FGF21 elevation [3, 48] . CKD-related factors could elevate circulating FGF21 levels because CKD represents a systemic or cellular metabolic stress, or CKD may cause FGF21 resistance in target organs [42, 49] as a result of downregulation of β-klotho or FGFR1c expression in target tissues. Obesity and inflammation can also downregulate β-klotho expression in adipose tissue [50] .
Not only in diabetic CKD patients, but CKD patients of any etiologies have some degree of glucose and lipid metabolism derangement. Insulin resistance (IR), metabolic syndrome and dyslipidemia are part of CKD pathophysiology. Muscle may be the primary site of IR in ESRD patients involving pro-inflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor (TNF)-α, oxidative stress, vitamin D deficiency, hyperparathyroidism, hyperleptinemia, metabolic acidosis and uremic toxins such as p-cresol sulfate [51, 52] . In IR, circulating insulin and glucagon levels increase along with lipolytic free fatty acids release from adipose tissue. Consequently, increased FGF21 expression and secretion by the liver augment glucose uptake by adipose tissue and muscles and re-establish metabolic balance.
ESRD patients develop muscle wasting, sarcopenia and frailty [53] . This can in part be explained by anemia, hormonal disorders, anorexia, metabolic acidosis, comorbidities, and sedentary lifestyle, resulting in lower muscle anabolism and higher catabolism [53] . Lately, skeletal muscle mitochondrial depletion and dysfunction have been characterized in CKD by impaired mitochondrial respiration, reduced muscle mitochondrial mass, depressed energy production and increased reactive oxygen species (ROS) generation in the skeletal muscle [54] [55] [56] . In congenital mitochondrial myopathies, circulating FGF21 levels are extremely high. If we consider the CKD-related myopathy as an acquired mitochondrial disease, high circulating FGF21 levels are also expected.
In addition to oxidative stress and proinflammatory cytokines, some uremic toxins can be implicated in CKDrelated mitochondrial dysfunction. Protein-bound uremic toxins such as indoxyl sulfate and p-cresol sulphate can impair mitochondrial biogenesis and activate mitochondrial autophagic machinery, reducing cellular mitochondrial mass and impairing cellular metabolism [57] . CKD-related mitochondrial dysfunction is documented only in skeletal muscles, but since uremic intoxication in ESRD is systemic other tissues may harbor mitochondrial dysfunction as well.
Adipose tissue in ESRD is known to be metabolically dysfunctional not only because of the presence of IR but Fig. 3 Mechanism of FGF21 elevation in chronic kidney disease. The loss of renal function contributes to decreased FGF21 clearance but probably not enough to explain the higher FGF21 levels in CKD patients. Beyond the liver, adipose tissue and skeletal muscles might become sources of FGF21 in CKD due to FGF21 resistance, insulin resistance, mitochondrial dysfunction, oxidative stress, inflammation, and actions of uremic toxins. Moreover, the FGF21 cleavage mediated by FAP might be altered in CKD also because of a derangement in the adipokine release pattern [58] . One such adipokine is leptin, which is a potential uremic toxin, and is implicated in CKD-related anorexia, muscle wasting and inflammation [59] . As an adipokine, FGF21 expression might be upregulated too.
There is some in vitro evidence that p-cresol sulphate and indoxyl sulphate can negatively affect adipose tissue metabolism inducing IR, adipose tissue atrophy, reactive oxygen species (ROS) and proinflammatory cytokine production [60, 61] . Visceral adipose tissue macrophages from human adipose tissue can be dysfunctional due to activation by free fatty acids and ceramide and may be implicated in proinflammatory cytokines release [62, 63] . The close interaction between adipocytes and macrophages in visceral adipose tissue might aggravate the adipocyte metabolic dysfunction and increase FGF21 gene expression.
In summary, the elevation in circulating FGF21 levels can be explained not only by its decreased renal clearance, but also by enhanced FGF21 secretion that may be driven by target tissue resistance, systemic metabolic derangement and cellular metabolic and noxious stress. It is probable that in conjunction with increased liver expression, there is a greater extrahepatic contribution of skeletal muscle and adipose tissue to systemic levels of FGF21.
FGF21 in preclinical experimental animal studies
The FGF21-transgenic over-expressing (FGF21-Tg) and deleted (FGF21 −/− ) mice are both viable with no specific phenotype at birth, and are metabolically indistinguishable from wild-type littermates under unperturbed physiological conditions at young age. However, as these mice age, FGF21-Tg mice are markedly smaller than their littermates and are resistant to diet-induced weight gain, even with increased food intake. In addition, the FGF21-Tg mice live about 30% longer than their wild-type littermates [1] and appear to be partially protected against chemically-induced malignancies [64] . On the other hand, the FGF21-Tg mice are prone to early onset of fasting-induced torpor [1] , and have reduction of bone mass and infertility [65, 66] .
Conversely, FGF21 −/− mice grow more than their wildtype littermates when pair-fed and moreover, they have increased bone mass [67] . Additionally, as these mice age, they develop mild obesity and impaired glucose homeostasis due to mild glucose intolerance. When FGF21 −/− mice are fed with a ketogenic diet (KD), they exhibit the full phenotype of FGF21 deficiency. In contrast to normal animals, which become ketotic and lose weight while on KD, FGF21 −/− mice have impaired ketosis and gain rather than lost weight. The FGF21 −/− mice also increase serum triglyceride levels and develop hepatic steatosis [68] .
In addition to all the well-known positive metabolic effects of recombinant FGF21 (rFGF21) treatment shown in experimental studies with obesity/diabetes animal models, many other studies have also suggested that FGF21 may have non-metabolic protective effects in different scenarios and organs. In exocrine pancreas, FGF21 is highly expressed in acinar cells under physiological conditions, and its expression is further enhanced by refeeding and chemically-induced pancreatitis [69] . In a cerulein-induced pancreatitis (CIP) mouse model, FGF21-Tg mice had less, while FGF21 −/− mice had more tissue damage than wild type mice [69] . Interestingly, in the Mist1 −/− mouse model of pancreatic injury, FGF21 expression was markedly decreased before and after CIP compared with wild-type mice due to epigenetic reprogramming that silences the FGF21 gene specifically in Mist1 −/− acinar cells. However, in FGF21-overexpressing Mist1 −/− mice, the pancreatic damage was partially mitigated [70] . FGF21 might be considered an exocrine pancreas secretagogue which stimulates digestive enzyme secretion from acinar cells through an autocrine/paracrine mechanism that requires FGFR and β-klotho. FGF21 −/− mice accumulate zymogen granules and are susceptible to pancreatic endoplasmic reticulum (ER) stress, an effect that was reversed by administration of rFGF21 [71] . FGF21 also exerts protective actions in pancreatic islets. FGF21 −/− mice exhibit increased β-cell proliferation, islet hyperplasia, insulin synthesis and are prone to periductal inflammation when fed with a high-fat diet. rFGF21 treatment reversed β-cell proliferation and islet dysfunction and inflammation [72, 73] .
In a high-fat diet-induced obesity (DIO) model, rFGF21 improved glucose and lipid metabolism, and reversed hepatic steatosis showing hepatic protective actions [74] . FGF21 was also protective in a murine model of acetaminophen-induced hepatotoxicity by enhancing the sirtuin 1 (SIRT1)/peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α)/nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated antioxidant capacity [75] . In a methionine and choline-deficient diet model of steatotic hepatitis, FGF21 −/− mice had more severe steatosis, fibrosis, inflammation and peroxidative damage than wild-type mice. In addition, after rFGF21 treatment, FGF21 −/− mice showed a reduction of steatosis and peroxidative damage, demonstrating that FGF21 limits lipotoxicity by promoting fatty acids β-oxidation, minimizing hepatic lipid accumulation and consequent ER stress [76] [77] [78] . Ethanol consumption robustly induces liver and serum FGF21 levels. With chronic ethanol consumption, FGF21 −/− mice had exaggerated alcohol-induced hepatic steatosis and liver injury, which was associated with increased activation of genes involved in lipogenesis mediated by sterol regulatory element-binding protein-1c (SREBP1c) and decreased expression of genes involved in fatty acid β-oxidation mediated by SIRT1/PGC1α and was reduced by rFGF21 treatment [79, 80] .
FGF21 also has cardioprotective actions in an endocrine and in an autocrine-paracrine fashion [41, 81] . As a cardiomyokine, FGF21 is expressed and released by cardiomyocytes under stressful conditions, and protects against isoproterenol, ischemia and doxorubicin-induced myocardial damage, reducing inflammation, apoptosis and remodeling [81] [82] [83] [84] . FGF21 is also protective against diabetic cardiomyopathy; FGF21 −/− diabetic mice show earlier and more severe cardiac dysfunction, remodeling and oxidative stress, as well as greater increase in cardiac lipid accumulation, which can be prevented by rFGF21 treatment [85] [86] [87] . Additionally, fenofibrate (a PPARα agonist) increased cardiac expression of FGF21 and prevented diabetes-induced cardiac dysfunction, inflammation and remodeling in wild-type diabetic mice, but not in FGF21 −/− mice, indicating that FGF21 might mediate fenofibrate cardio-protective effects [88] . In vitro studies showed that FGF21 protects cardiomyocytes by increasing antioxidant, autophagy and mitochondrial biogenesis and oxidative capacities, reducing ER stress and suppressing inflammatory and apoptosis pathways [85, [87] [88] [89] [90] .
FGF21 is protective in murine models of diabetic nephropathy (DN) and FFA-induced nephropathy (lipotoxic model) as evident by reduction of proteinuria, suppression of mesangial expansion, and inhibition of fibrosis [7, 8] . Furthermore, FGF21 improved renal lipid metabolism and oxidative stress injury. FGF21 gene deletion further enhances the pathological damage while rFGF21 replenishment significantly prevents it [7, 8, 91] . Fenofibrate protects against type 1 DN by FGF21-mediated upregulation of the nuclear factor E2-related factor 2 (Nrf2) antioxidant pathway [92] . In cisplatin-induced acute kidney injury (AKI), silencing of FGF21 aggravated tubular cell injury, whereas supplementation of rFGF21 protected against cisplatin nephrotoxicity [7, 8, 93] .
FGF21 is associated with atherosclerosis in clinical studies, and FGF21 deficiency causes a marked exacerbation of atherosclerotic plaque formation and premature death in apoE knockout mice [94] . Replenishment of FGF21 protects against atherosclerosis indirectly by inducing adipose tissue production of adiponectin and suppressing the hepatic cholesterol synthesis, leading to attenuation of hypercholesterolemia [94] , and directly by preventing ER stress-mediated apoptosis of endothelial cells and macrophages [95] , enhancing cholesterol efflux from macrophages blocking its conversion to foam cells [96, 97] , and inhibiting smooth muscle cells proliferation and calcification [98, 99] . Finally, limited data suggest protective actions of FGF21 in the lung, attenuating fibrosis though activating the Nrf2 pathway, and in a sepsis model by enhancing animal survival [100] [101] [102] .
FGF21 in human CKD: observational data
Serum FGF21 levels correlate positively with creatinine, blood-urea-nitrogen (BUN) and cystatin C and inversely with the GFR and residual renal function. Some studies showed the same positive correlation found in the general population between FGF21 serum levels and metabolic syndrome-related parameters such as body mass index (BMI), TG, high low-density lipoprotein (LDL) and low high-density lipoprotein (HDL) cholesterol, glycemia, and homeostasis model assessment of insulin resistance (HOMA-IR), as well as between FGF21 and other adipokines, such as leptin and adiponectin. However, these correlations seem to depend on the diabetic state and CKD stage. Similarly, FGF21 serum levels correlate positively with inflammatory markers such as IL-6, hrCRP, β-microglobulin and fibrinogen [2, 3, 15, 44, 45, [103] [104] [105] .
FGF21 levels were higher in 200 CKD patients (146 pre-dialysis and 54 hemodialysis patients) than in 40 controls [105] . Even patients with early CKD stage (eGFR > 60 ml/min/1.73 m 2 ) already had double the level of serum FGF21 compared to the control group, and there was a progressive increase with worsening of CKD stage. An interesting finding was the positive correlation between serum FGF21 and serum phosphorus levels, as well as with the presence of left ventricular hypertrophy by echocardiogram, two important markers of cardiovascular risk in the dialysis population [105] .
In 499 CKD patients from stages 1 to 5, renal function was a primary independent predictor of serum FGF21 levels, with > 20-fold increase in serum FGF21 levels from stage 1 to stage 5, showing a linear correlation between CKD stage and FGF21 levels. In acute renal mass reduction in 32 patients who underwent unilateral (partial or total) nephrectomy, there was a significant increase in serum levels of FGF21 and inflammatory markers (hrCRP and IL-6) 30 h after surgery [2] . Therefore, renal injury, damage, or mass reduction contribute to elevation of serum FGF21.
When 72 non-diabetic peritoneal dialysis (PD) patients were compared with 63 control subjects, PD patients had eight times higher serum FGF21 levels. There was a negative correlation between FGF21 levels and residual renal function, but a positive correlation with HOMA-IR and fibrinogen levels. There was a reduction in serum FGF21 levels, HOMA-IR, hrCRP, fibrinogen after 6 months use of Valsartan [44] . In another PD study in 56 continuous ambulatory peritoneal dialysis patients, a negative correlation was observed between serum levels of FGF21 and flow-mediated dilation, a marker of endothelial function. But no correlation was observed between oxidative stress markers and hepcidin with serum FGF21 [104] .
Over 3 years, with annual measurement of serum FGF21, there was progressive elevation with dialysis vintage, a negative correlation with residual renal function, and a positive correlation with peritoneal protein loss. However, no correlation was observed between serum FGF21 levels and parameters related to glucose metabolism such as HOMA-IR, fasting glycemia and insulin levels [45] . Despite the very high serum FGF21 levels in hemodialysis patients, serial FGF21 measurements over a period of 8 h in 12 nondiabetic HD patients showed that the increment to meal intake or glucose/insulin infusion remains preserved even though in a lower extent than in control patients [46] .
There is an association between serum FGF21 levels and the rate of cardiovascular events and mortality in HD patients. Ninety HD patients were divided into two groups (low vs. high FGF21) at baseline and followed for 64 months. A higher overall mortality was observed in the high-FGF21 group, but a higher incidence of cardiovascular events was not observed. In a multivariate and adjusted analysis, elevated FGF21 levels were shown to be an independent predictor of all-cause mortality in this population [3] . One fact about all these observational studies is that only the total levels of FGF21 were measured by the ELISA technique. There are no data on C-terminal or N-terminal fragments, or intact FGF21.
FGF21 and diabetic nephropathy
Independently of CKD, FGF21 levels are elevated in obese individuals with metabolic syndrome and those with T2D where there may be some degree of FGF21 resistance. DN is the leading cause of ESRD in the world, with a complex pathophysiology involving both glucotoxicity and lipotoxicity, triggering oxidative stress and inflammation [106, 107] . T2D patients have a positive correlation between serum FGF21 levels and urinary albumin excretion. Serum FGF21 levels progressively increase in parallel with the progression from normal to microalbuminuria and from micro to overt albuminuria, even before an impairment of renal function becomes apparent. It appears that serum FGF21 level is strongly associated with the onset of nephropathy in T2D patients and is an independent predictor of loss of renal function in these patients [4] [5] [6] .
FGF21 expression has been proposed both in mesangial cells and in tubular cells of diabetic mouse kidneys [7] . In cultured renal cells, FGF21 expression was observed in mesangial cells, and blockade of FGF21 expression aggravates high-glucose-induced profibrotic cytokine synthesis [9] . In experimental metabolic syndrome in db/db mice, there was increased FGF21 expression, β-klotho, and FGFR1c and FGFR2c in renal tissue, which decreased after rFGF21 therapy. rFGF21 administration also markedly decreased albuminuria, mesangial cell expansion, profibrotic cytokines, and improved kidney lipid metabolism and oxidative stress injury [7] .
As mentioned earlier, the FGF21 −/− mice receiving free fatty acids, or induced to have diabetes by streptozotocin, had more intense damage than the wild type animals. In addition, rFGF21 administration significantly prevented both free fatty acids-induced and diabetes-induced kidney injury, by decreasing lipid accumulation, inflammation, oxidative stress and reducing fibrosis [8] .
It seems that FGF21 can improve not only systemic glucose and lipid metabolism in diabetic patients, but also protect tissues such as kidneys and myocardium from the deleterious effect of insulin resistance and lipids accumulation, which would lead to glucotoxicity and lipotoxicity, inflammation, oxidative stress and finally fibrosis.
Significance of high FGF21 levels in CKD
The pathophysiological significance of increased serum FGF21 concentrations in ESRD remains undefined. It is also not known whether the very high levels of FGF21 in ESRD patients represent an adaptation or maladaptation, i.e. whether it is protective or deleterious to the patient.
This conundrum stems mainly from apparently disparate findings from population correlative data vs. animal experimental studies. There are several possible explanations for this apparent conflict. First, that the high FGF21 in human CKD is in fact adaptive in response to multiple noxious stimuli but inadequate to ameliorate the uremic complications. An analogy would be the high natriuretic peptide in heart failure, which is adaptive but inadequate. In this case, blocking or lowering of FGF21 may have a minimal therapeutic effect. Second, high FGF21 is in fact adaptive but the unrelenting need for more FGF21 drives it to such high levels that are harmful perhaps due to off-target effects. An analogy would be secondary hyperparathyroidism. In this scenario, lowering or blocking FGF21 may confer benefits. FGF21's close relative FGF23 is still undergoing this debate but the data is gravitating toward the latter model for FGF23.
The pharmacological dose used to treat diabetes in animals leads to circulating FGF21 levels much higher than the physiological range or even the levels seen in ESRD [108] . Pharmacological FGF21 treatment usually increases energy expenditure while it can induce anorexia, resulting in weight loss [20, 109] . These effects are desirable for the obese and diabetic animal or patient, but for ESRD patients they may or may not be desired.
Another potentially harmful effect found for non-CKD patients, but probably amplified in ESRD patients, is a negative impact on bone with increased bone reabsorption and decreased bone formation [110, 111] . This is due to the ability of FGF21 to inhibit osteoblastogenesis and stimulate adipogenesis from bone marrow mesenchymal stem cells by potentiating the activity of peroxisome proliferator-activated receptor γ (PPAR-γ) [66] . In addition, FGF21 may impair the action of growth hormone and may participate in the growth retardation process observed in children with ESRD [112] .
FGF21 can cross the blood-brain barrier and induce numbness, decrease gonadotropin-releasing hormone, increase corticotrophin-releasing factor and sympathetic nervous system activity [26] . Thus far, there are no human data on the effects of FGF21 on the central nervous system.
Conclusion
The progressively higher FGF21 levels that appear in parallel with renal function deterioration could not be explained solely by the loss of renal clearance, leading to the supposition that CKD specific factors may contribute to increased FGF21 synthesis from yet undetermined sources. Figure 4 summarizes the models that may explain the preclinical and observational findings. Although serum FGF21 levels correlate with increased mortality in the CKD/ESRD population and faster progression of diabetic nephropathy, preclinical studies are supportive of protective effects of FGF21, including a reduction of glucotoxicity and lipotoxicity, oxidative stress and inflammation, and increasing autophagy and decreasing apoptosis. A possible explanation for this apparent discrepancy would be that FGF21 functions as a stress-responsive factor putting in motion mechanisms of cellular self-protection. Somehow, this "adaptive" increase is not adequate to alleviate the renal damage and progression of CKD. This can be compared to elevated atrial natriuretic peptides in heart failure as a reflection of volume overload, but the heightened atrial natriuretic peptide is not sufficient to rectify the volume overload.
There is clearly a hidden story about the role of FGF21 in CKD yet to be told. This story must answer, among others, questions such as: What is the relative role of reduced renal clearance vs. increased FGF21 production in elevating FGF21 in CKD? Which tissue (liver, adipose tissue, skeletal muscle, heart, or kidneys) is contributing to the serum FGF21 level? And does the contribution of different tissues to elevation of serum FGF21 depend upon the disease scenario? If increased production is the main mechanism, what factors are driving the increased production? What is the proportion between active and inactive forms of FGF21 that circulate in CKD patients? Is FGF21 a friend or a foe, i.e. adaptive vs. maladaptive? Is it conceivable that it starts out as adaptive in early CKD and then there is a transition to a maladaptive response? As an eventual epilogue to this story, we need to evaluate the therapeutic effect of FGF21 replacement on nephropathy, cardiomyopathy and vascular disease in CKD patients if FGF21 elevation is a protective but insufficient response to injury or stress. 
